Evidence map›Paper›PMID 39424747›Full record

ArticleAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2025

The Influence of High Body Mass Index (BMI > 35 kg/m

May Hilu, Mariana Issawy, Raul Colodner, Harel Eitam, Gilat Ron Avraham, Kerstin Carlin Ram, Mazen Elias, Orli Shimoni, Eyal Schwartzberg, Lee Hilary Goldstein

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of cardiovascular drugs : drugs, devices, and other interventions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

May HiluPharmacy Department, Clalit Healthcare, North District, Nof Hagalil, Israel.
Mariana IssawyTechnion Israel Institute of Technology, Rappaport Faculty of Medicine, Haifa, 3109601, Israel.ORCID http://orcid.org/0009-0000-2269-8292
Raul ColodnerCentral Laboratory, HaEmek Medical Center, Afula, Israel.
Harel EitamCentral Laboratory, HaEmek Medical Center, Afula, Israel.
Gilat Ron AvrahamTechnion Israel Institute of Technology, Rappaport Faculty of Medicine, Haifa, 3109601, Israel.
Kerstin Carlin RamTechnion Israel Institute of Technology, Rappaport Faculty of Medicine, Haifa, 3109601, Israel.
Mazen EliasTechnion Israel Institute of Technology, Rappaport Faculty of Medicine, Haifa, 3109601, Israel.
Orli ShimoniSchool of Pharmacy, Ben Gurion University of the Negev, Beersheba, Israel.
Eyal SchwartzbergSchool of Pharmacy, Ben Gurion University of the Negev, Beersheba, Israel.
Lee Hilary GoldsteinTechnion Israel Institute of Technology, Rappaport Faculty of Medicine, Haifa, 3109601, Israel. goldstei@technion.ac.il.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeApixaban, a direct oral anticoagulant is administered for stroke prevention in atrial fibrillation patients. Dosing adjustment is guided by renal function, age, and body weight. However, no data exist on its pharmacokinetics in patients with a body mass index (BMI) ≥ 35 kg/m

methodsThis prospective study compared steady-state trough concentrations of apixaban in patients with a BMI ≥ 35 kg/m

resultsSixty patients were included. In patients receiving 5 mg apixaban twice daily, the median trough plasma concentration was 29% lower in patients with a BMI ≥ 35 kg/m

conclusionBMI ≥ 35 kg/m

Indexed as

Atrial FibrillationBody Mass IndexFactor Xa InhibitorsPyrazolesPyridonesAgedAged, 80 and overFemaleHumansMaleMiddle AgedProspective StudiesStrokeapixabanFactor Xa InhibitorsPyrazolesPyridones

Identifiers

PMID39424747
PMCPMC11775066

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.